Senior care startup Sage raised $65 million led by Goldman Sachs Alternatives to scale Sage Detect, an AI monitoring system that predicts falls before they happen; the company cites a 50% drop in falls and $275 per-resident monthly NOI gains in communities already using it.
MyFitnessPal acquired Cal AI, a photo-based calorie-counting app built by 19-year-old Zach Yadegari that generates over $30 million in annual revenue and has logged more than 15 million downloads in under two years.
An Imperial College London AI model reads routine ECGs in under two seconds, detecting heart failure in up to 81% of cases and aortic valve disease in up to 90%, and is now being trialled on 590 NHS patients across London and Bristol.
New 2026 survey data shows consumer preference for human customer service climbing to 85% while trust in AI-run support erodes, with refund disputes emerging as the clearest flashpoint for chatbot failures.
The pivotal DERM-SUCCESS study found the FDA-cleared DermaSensor device helped primary care physicians correctly refer 91.4 percent of malignant skin lesions versus 82.0 percent without it, a 52 percent cut in missed skin cancer referrals.
Sinai Hospital in Baltimore has deployed Prenosis' FDA-authorized Sepsis ImmunoScore, an AI tool that analyzes 22 clinical parameters to flag sepsis risk up to 24 hours before deterioration, part of a growing real-world rollout of the first AI diagnostic cleared specifically for sepsis.
Stanford Medicine researchers led by James Zou published a Science paper on September 17, 2026, describing a 37,000-agent AI virtual biotech that independently proposed a lung cancer treatment strategy later validated by a real pharmaceutical trial.
A major September 28, 2026 review shows how AI is combining gut microbiome, genetic, and metabolic data to generate truly individualized diet advice, though researchers caution the science hasn't yet caught up to consumer marketing claims.
A Yale School of Medicine study found that fine-tuning AI models on more than 13,000 patient records raised diagnostic accuracy from 48.6 to 54.8 percent, but also made the models far more likely to memorize and potentially leak sensitive patient details.
Moderna and Merck announced on August 19, 2026 that their AI-designed, patient-specific mRNA melanoma vaccine met its main goals in a Phase 3 trial, the first randomized late-stage success for an individualized cancer vaccine.